Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220912881> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4220912881 endingPage "107424842210847" @default.
- W4220912881 startingPage "107424842210847" @default.
- W4220912881 abstract "Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple causative pathways has been growing. Several medications including icosapent ethyl, rivaroxaban, and ezetimibe have been shown to individually improve outcomes in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) beyond conventional therapy consisting of aspirin and statins. While each drug has been shown to individually improve outcomes, the expected treatment benefit of the combined use of these drugs for enhanced secondary prevention of ASCVD is not known. Methods: In this cross-trial analysis, we estimated the aggregate treatment effect of comprehensive medical therapy consisting of icosapent ethyl, rivaroxaban, and ezetimibe added to background aspirin and statin therapy through established methods of indirect comparisons of the results of three key clinical trials (REDUCE-IT [n = 8,179], COMPASS [n = 27,395], and IMPROVE-IT [n = 18,144]). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke. Secondary endpoints included each individual component of the primary endpoint. Results: The hazard ratio (HR) of the imputed aggregate treatment effects for enhanced secondary prevention of ASCVD with comprehensive disease modifying therapy compared to aspirin and statin alone for the primary endpoint was 0.51 (95% confidence interval [CI] 0.42-0.61). The HR for CV death was 0.62 (95% CI 0.46-0.85), non-fatal MI was 0.52 (95% CI 0.40-0.69), and non-fatal stroke was 0.35 (95% CI 0.23-0.54). The results were similar in sensitivity analyses. Conclusion: The estimated aggregate treatment effect of enhanced secondary prevention of ASCVD through comprehensive medical therapy is substantial. This exploratory analysis supports further study of comprehensive therapy to reduce residual CV risk for the secondary prevention of ASCVD." @default.
- W4220912881 created "2022-04-03" @default.
- W4220912881 creator A5020084134 @default.
- W4220912881 creator A5085601482 @default.
- W4220912881 date "2022-01-01" @default.
- W4220912881 modified "2023-10-18" @default.
- W4220912881 title "Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease" @default.
- W4220912881 cites W1275357281 @default.
- W4220912881 cites W1520609538 @default.
- W4220912881 cites W2023939263 @default.
- W4220912881 cites W2035636901 @default.
- W4220912881 cites W2082209076 @default.
- W4220912881 cites W2137298866 @default.
- W4220912881 cites W2749380187 @default.
- W4220912881 cites W2899669642 @default.
- W4220912881 cites W2899997727 @default.
- W4220912881 cites W2920558304 @default.
- W4220912881 cites W2920910705 @default.
- W4220912881 cites W2981766629 @default.
- W4220912881 cites W2997615115 @default.
- W4220912881 cites W3023479981 @default.
- W4220912881 cites W3024277681 @default.
- W4220912881 cites W3026507424 @default.
- W4220912881 cites W3028175580 @default.
- W4220912881 cites W3032672310 @default.
- W4220912881 cites W3129818723 @default.
- W4220912881 cites W3149508638 @default.
- W4220912881 cites W3174871823 @default.
- W4220912881 doi "https://doi.org/10.1177/10742484221084772" @default.
- W4220912881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35259008" @default.
- W4220912881 hasPublicationYear "2022" @default.
- W4220912881 type Work @default.
- W4220912881 citedByCount "0" @default.
- W4220912881 crossrefType "journal-article" @default.
- W4220912881 hasAuthorship W4220912881A5020084134 @default.
- W4220912881 hasAuthorship W4220912881A5085601482 @default.
- W4220912881 hasBestOaLocation W42209128811 @default.
- W4220912881 hasConcept C126322002 @default.
- W4220912881 hasConcept C127413603 @default.
- W4220912881 hasConcept C164705383 @default.
- W4220912881 hasConcept C203092338 @default.
- W4220912881 hasConcept C207103383 @default.
- W4220912881 hasConcept C2776301958 @default.
- W4220912881 hasConcept C2776839432 @default.
- W4220912881 hasConcept C2777628954 @default.
- W4220912881 hasConcept C2778657065 @default.
- W4220912881 hasConcept C2778661090 @default.
- W4220912881 hasConcept C2779161974 @default.
- W4220912881 hasConcept C2780645631 @default.
- W4220912881 hasConcept C44249647 @default.
- W4220912881 hasConcept C500558357 @default.
- W4220912881 hasConcept C535046627 @default.
- W4220912881 hasConcept C71924100 @default.
- W4220912881 hasConcept C78519656 @default.
- W4220912881 hasConceptScore W4220912881C126322002 @default.
- W4220912881 hasConceptScore W4220912881C127413603 @default.
- W4220912881 hasConceptScore W4220912881C164705383 @default.
- W4220912881 hasConceptScore W4220912881C203092338 @default.
- W4220912881 hasConceptScore W4220912881C207103383 @default.
- W4220912881 hasConceptScore W4220912881C2776301958 @default.
- W4220912881 hasConceptScore W4220912881C2776839432 @default.
- W4220912881 hasConceptScore W4220912881C2777628954 @default.
- W4220912881 hasConceptScore W4220912881C2778657065 @default.
- W4220912881 hasConceptScore W4220912881C2778661090 @default.
- W4220912881 hasConceptScore W4220912881C2779161974 @default.
- W4220912881 hasConceptScore W4220912881C2780645631 @default.
- W4220912881 hasConceptScore W4220912881C44249647 @default.
- W4220912881 hasConceptScore W4220912881C500558357 @default.
- W4220912881 hasConceptScore W4220912881C535046627 @default.
- W4220912881 hasConceptScore W4220912881C71924100 @default.
- W4220912881 hasConceptScore W4220912881C78519656 @default.
- W4220912881 hasLocation W42209128811 @default.
- W4220912881 hasLocation W42209128812 @default.
- W4220912881 hasOpenAccess W4220912881 @default.
- W4220912881 hasPrimaryLocation W42209128811 @default.
- W4220912881 hasRelatedWork W1972702180 @default.
- W4220912881 hasRelatedWork W2024334311 @default.
- W4220912881 hasRelatedWork W2089715561 @default.
- W4220912881 hasRelatedWork W2097281569 @default.
- W4220912881 hasRelatedWork W2117378160 @default.
- W4220912881 hasRelatedWork W2174666533 @default.
- W4220912881 hasRelatedWork W2307397775 @default.
- W4220912881 hasRelatedWork W4220912881 @default.
- W4220912881 hasRelatedWork W4362588076 @default.
- W4220912881 hasRelatedWork W2461326802 @default.
- W4220912881 hasVolume "27" @default.
- W4220912881 isParatext "false" @default.
- W4220912881 isRetracted "false" @default.
- W4220912881 workType "article" @default.